Irbesartan/propagermanium

Drug Profile

Irbesartan/propagermanium

Alternative Names: DMX-200

Latest Information Update: 05 Aug 2016

Price : $50

At a glance

  • Originator Dimerix Bioscience
  • Class Biphenyl compounds; Organometallic compounds; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; CCR2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Focal segmental glomerulosclerosis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Renal failure

Most Recent Events

  • 14 Sep 2015 Phase-II clinical trials in Renal failure in Australia (PO)
  • 29 Dec 2014 Irbesartan/propagermanium is available for licensing as of 01 Jun 2014.
  • 01 Jan 2013 Pharmacodynamics results from preclinical studies in Chronic kidney disease and proteinuria presented at the Annual Meeting of the American Society for Nephrology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top